Publications
Detailed Information
Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappa B activity in hypoxic tumor cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, G-Y | - |
dc.contributor.author | Jeon, J-H | - |
dc.contributor.author | Cho, S-Y | - |
dc.contributor.author | Jeong, E. M. | - |
dc.contributor.author | Bae, H. C. | - |
dc.contributor.author | Kim, C-W | - |
dc.contributor.author | Shin, D-M | - |
dc.contributor.author | Kim, T. W. | - |
dc.contributor.author | Choi, Y. | - |
dc.contributor.author | Kim, I-G | - |
dc.contributor.author | Park, S-C | - |
dc.contributor.author | Lee, D-S | - |
dc.contributor.author | Lee, S-H | - |
dc.date.accessioned | 2012-05-22T05:52:52Z | - |
dc.date.available | 2012-05-22T05:52:52Z | - |
dc.date.issued | 2010-01-21 | - |
dc.identifier.citation | ONCOGENE; Vol.29 3; 356-367 | ko_KR |
dc.identifier.issn | 0950-9232 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76232 | - |
dc.description.abstract | The expression of hypoxia-inducible factor-1 (HIF-1) correlates with poor clinical outcomes and confers resistance to the apoptosis of the tumor cells that are exposed to hypoxia. Presently, the mechanism underlying this phenomenon is poorly understood. In this study we provide evidence that transglutaminase 2 (TG2), an enzyme that catalyses protein crosslinking reactions, is a transcriptional target of HIF-1 to enhance the survival of hypoxic cells. We found that hypoxia induces TG2 expression through an HIF-1 dependent pathway and concurrently activates intracellular TG2. The hypoxic cells overexpressing TG2 showed resistance to apoptosis. Conversely, the hypoxic cells treated with either TG2 inhibitor or small interfering RNA (siRNA) became sensitive to apoptosis. Activation of TG2 in response to hypoxic stress inhibited caspase-3 activity by forming crosslinked multimer, resulting in insoluble aggregates. TG2 also activates nuclear factor (NF)-kappa B pathway after hypoxic stress, and thereby induces the expression of cellular inhibitor of apoptosis 2. The anti-apoptotic role of TG2 was further confirmed in vivo using xenografts in athymic mice. Our results indicate that TG2 is an antiapoptotic mediator of HIF-1 through modulating both apoptosis and survival pathways and may confer a selective growth advantage to tumor cells. These findings suggest that the inhibition of TG2 may offer a novel strategy for anticancer therapy. Oncogene (2010) 29, 356-367; doi:10.1038/onc.2009.342; published online 19 October 2009 | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | NATURE PUBLISHING GROUP | ko_KR |
dc.subject | apoptosis | ko_KR |
dc.subject | caspase 3 | ko_KR |
dc.subject | hypoxia-inducible factor-1 | ko_KR |
dc.subject | transglutaminase 2 | ko_KR |
dc.subject | NF-kappa B | ko_KR |
dc.title | Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappa B activity in hypoxic tumor cells | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1038/onc.2009.342 | - |
dc.citation.journaltitle | ONCOGENE | - |
dc.description.citedreference | Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889 | - |
dc.description.citedreference | Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262 | - |
dc.description.citedreference | Baldwin AS, 2001, J CLIN INVEST, V107, P241 | - |
dc.description.citedreference | De Laurenzi V, 2001, MOL CELL BIOL, V21, P148 | - |
dc.description.citedreference | Wykoff CC, 2000, ONCOGENE, V19, P6297 | - |
dc.description.citedreference | Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425 | - |
dc.description.citedreference | Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936 | - |
dc.description.citedreference | Park SS, 2006, J BIOL CHEM, V281, P34965, DOI 10.1074/jbc.M604150200 | - |
dc.description.citedreference | Antonyak MA, 2006, P NATL ACAD SCI USA, V103, P18609, DOI 10.1073/pnas.0604844103 | - |
dc.description.citedreference | KUHLICKE J, 2007, PLOS ONE, V2, pC1364 | - |
dc.description.citedreference | Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083 | - |
dc.description.citedreference | Verma A, 2007, DRUG RESIST UPDATE, V10, P144, DOI 10.1016/j.drup.2007.06.002 | - |
dc.description.citedreference | Shin DM, 2008, FASEB J, V22, P2498, DOI 10.1096/fj.07-095455 | - |
dc.description.citedreference | Filiano AJ, 2008, FASEB J, V22, P2662, DOI 10.1096/fj.07-097709 | - |
dc.description.citedreference | Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187 | - |
dc.description.citedreference | Dirmeier R, 2004, METHOD ENZYMOL, V381, P589 | - |
dc.description.citedreference | Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200 | - |
dc.description.citedreference | Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367 | - |
dc.description.citedreference | Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200 | - |
dc.description.citedreference | Aggarwal BB, 2004, CANCER CELL, V6, P203 | - |
dc.description.citedreference | Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200 | - |
dc.description.citedreference | Mehta K, 2004, CLIN CANCER RES, V10, P8068 | - |
dc.description.citedreference | Jeon JH, 2004, EXP MOL MED, V36, P576 | - |
dc.description.citedreference | Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937 | - |
dc.description.citedreference | Jeon JH, 2003, FEBS LETT, V534, P180, DOI 10.1016/S0014-5793(02)03836-X | - |
dc.description.citedreference | Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014 | - |
dc.description.citedreference | Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222 | - |
dc.description.citedreference | Zhang ZB, 2003, CIRC RES, V92, P1153, DOI 10.1161/01.RES.0000071749.22027.45 | - |
dc.description.citedreference | Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084 | - |
dc.description.citedreference | Jeon JH, 2003, EMBO J, V22, P5273 | - |
dc.description.citedreference | Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199 | - |
dc.description.citedreference | Choi K, 2005, CHEM BIOL, V12, P469, DOI 10.1016/j.chembiol.2005.02.007 | - |
dc.description.citedreference | Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001 | - |
dc.description.citedreference | Yuan L, 2005, MOL CANCER THER, V4, P1293, DOI 10.1158/1535-7163.MCT-04-0328 | - |
dc.description.citedreference | Yamaguchi H, 2006, MOL CELL BIOL, V26, P569, DOI 10.1128/MCB.26.2.569-579.2006 | - |
dc.description.citedreference | Hui AS, 2006, FASEB J, V20, P466, DOI 10.1096/fj.05-5086com | - |
dc.description.citedreference | Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324 | - |
dc.description.citedreference | Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871 | - |
dc.description.citedreference | Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538 | - |
dc.description.citedreference | Brunelle JK, 2002, APOPTOSIS, V7, P475 | - |
dc.description.citedreference | Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534 | - |
dc.description.citedreference | Zagzag D, 2000, CANCER, V88, P2606 | - |
dc.description.citedreference | Baylin SB, 1997, SCIENCE, V277, P1948 | - |
dc.description.citedreference | Dachs GU, 1997, NAT MED, V3, P515 | - |
dc.description.citedreference | LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370 | - |
dc.description.tc | 11 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.